Compare CCJ & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCJ | EW |
|---|---|---|
| Founded | 1987 | 1958 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Industrial Specialties |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.8B | 50.2B |
| IPO Year | 1998 | 1999 |
| Metric | CCJ | EW |
|---|---|---|
| Price | $111.23 | $86.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 21 |
| Target Price | ★ $123.92 | $96.37 |
| AVG Volume (30 Days) | 2.9M | ★ 4.3M |
| Earning Date | 05-05-2026 | 04-23-2026 |
| Dividend Yield | ★ 0.15% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.66 |
| Revenue | N/A | ★ $6,067,600,000.00 |
| Revenue This Year | $0.12 | $13.39 |
| Revenue Next Year | $12.11 | $9.81 |
| P/E Ratio | ★ $118.32 | $131.25 |
| Revenue Growth | N/A | ★ 11.55 |
| 52 Week Low | $57.63 | $72.30 |
| 52 Week High | $135.24 | $88.28 |
| Indicator | CCJ | EW |
|---|---|---|
| Relative Strength Index (RSI) | 48.38 | 63.10 |
| Support Level | $109.59 | $81.39 |
| Resistance Level | $124.38 | $87.22 |
| Average True Range (ATR) | 4.41 | 2.52 |
| MACD | -0.41 | 0.62 |
| Stochastic Oscillator | 46.02 | 86.85 |
Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe and is one of those uranium producers. It has three reportable segments: Uranium, Fuel Services, and Westinghouse, deriving maximum revenue from the Westinghouse segment. The Uranium segment involves the exploration for, mining, milling, purchase, and sale of uranium concentrate, while the Fuel Services segment involves the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. Westinghouse Electric Company provides products and services to nuclear reactors, including outage and maintenance services, engineering support, instrumentation and controls equipment, plant modification, and components and parts.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.